MOUNTAIN VIEW, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 10:30 a.m.
-- Companies plan to file for full marketing approval to EMA and FDA in 2020 -- MOUNTAIN VIEW, Calif. and ZURICH, Switzerland, Jan. 24, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd. , a company of Vifor Pharma Group , today announced that in light of
MOUNTAIN VIEW, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 1:30 p.m. PST .
-- Studies highlight CCX4503, a unique small molecule inhibitor of immune checkpoint molecules PD-1/PD-L1, demonstrates anti-tumor efficacy in vivo -- -- Company’s studies also show CCR4 inhibition enhances effectiveness of checkpoint inhibition in tumor models in vivo -- MOUNTAIN VIEW, Calif.
MOUNTAIN VIEW, Calif. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday November 27, 2018 at 8:30 a.m. ET .
-- Large, controlled clinical trial of avacopan in Hidradenitis Suppurativa (HS) on track to launch in late 2018 – -- $186 million in cash and investments at September 30, 2018 -- -- Received Orphan Drug Designation for CCX140 in Focal Segmental Glomerulosclerosis (FSGS) -- -- Conference call today
MOUNTAIN VIEW, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's third quarter 2018 financial results will be released after market close on Thursday, November 8, 2018 . ChemoCentryx executive management will host a conference call
-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ADVOCATE Phase III Pivotal Trial in ANCA-Associated Vasculitis -- -- Reveals Potential New Role for Chemokine Receptor 2 (CCR2) in the Treatment of Focal Segmental Glomerulosclerosis (FSGS) with First
MOUNTAIN VIEW, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (the "Company" or "ChemoCentryx") (Nasdaq:CCXI) announced today that it will not conclude an offering of shares of its common stock as announced on Wednesday, September 26, 2018 .
MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of $75 million of its common stock. In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to
